ClinicalTrials.gg
RecruitingNCT07372170DOACS-APSUpdated Jan 30, 2026

Observational Study to Evaluate the Effectiveness of DOACS for Secondary Thrombosis Prevention in Low-risk Thrombotic APS Patients

An observational study in Antiphospholipid Syndrome (APS), Venous Thrombosis (Disorder) and Thrombophilia, sponsored by Infanta Leonor University Hospital. Recruiting at 2 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by Infanta Leonor University Hospital · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
600
Ages
18 Years and older
Sex
All
01

Study summary

This is an observational study designed to evaluate the effectiveness and safety of direct oral anticoagulants (DOACs) compared with vitamin K antagonists (VKAs) for the secondary prevention of thrombosis in patients with low-risk thrombotic antiphospholipid syndrome.

Antiphospholipid syndrome is an autoimmune disorder associated with an increased risk of thrombotic events. Although VKAs have traditionally been the standard treatment, DOACs are increasingly used in clinical practice in selected patients, despite limited evidence in this setting.

This study includes patients with previous venous thrombosis and a low-risk serological profile who are treated with either DOACs or VKAs according to routine clinical practice. The primary objective is to compare thrombotic recurrence and bleeding events between both treatment strategies.

The results of this study will contribute to improving knowledge about the use of DOACs in patients with low-risk thrombotic antiphospholipid syndrome.

Read the detailed description

Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the occurrence of arterial, venous, or small-vessel thrombosis in the presence of persistent antiphospholipid antibodies. Patients with thrombotic APS have a high risk of recurrent thrombosis and require long-term anticoagulation. Vitamin K antagonists (VKAs) have traditionally been the treatment of choice in this population.

Direct oral anticoagulants (DOACs) have demonstrated efficacy and safety in other clinical settings, such as venous thromboembolism and non-valvular atrial fibrillation. However, their use in APS remains controversial following randomized clinical trials that showed an increased risk of arterial thrombotic events, particularly in patients with high-risk serological profiles.

Current clinical guidelines suggest that DOACs may be considered in selected patients with low-risk thrombotic APS, defined by venous thrombosis and the absence of triple antiphospholipid antibody positivity. Nevertheless, evidence supporting their use in this specific subgroup is limited.

This observational, analytical, ambispective (retrospective and prospective) study aims to evaluate the effectiveness and safety of DOACs compared with VKAs in patients with low-risk thrombotic APS under routine clinical practice conditions.

Adult patients with a diagnosis of low-risk thrombotic APS who are receiving treatment with DOACs or VKAs at the time of inclusion will be eligible. Anticoagulant therapy will be prescribed at the discretion of the treating physician, with no intervention by the study protocol.

The primary objective is to assess a combined effectiveness and safety endpoint, including thrombotic recurrence and major or clinically relevant bleeding. Secondary objectives include all-cause mortality, cardiovascular mortality, and treatment-related quality of life assessed using the Anti-Clot Treatment Scale (ACTS).

The study will be conducted in Internal Medicine units across Spain and is expected to provide relevant real-world evidence to support clinical decision-making in the anticoagulant management of patients with low-risk thrombotic antiphospholipid syndrome.

02

Conditions studied

  • Antiphospholipid Syndrome (APS)
  • Venous Thrombosis (Disorder)
  • Thrombophilia

Keywords

  • Direct oral anticoagulants
  • Vitamin K antagonists
  • Low-risk antiphospholipid syndrome
  • Secondary thrombosis prevention
  • Real-world study
  • Observational study
  • Venous Thrombosis
  • Antiphospholipid Antibody Profile
03

In context

Antiphospholipid Syndrome

121 studies on the registry are indexed under Antiphospholipid Syndrome; 52 are open to participants now.

This study's planned enrollment of 600 is above the median of 156 across 50 observational studies indexed under Antiphospholipid Syndrome.

Browse Antiphospholipid Syndrome studies →

Lead sponsor

Infanta Leonor University Hospital is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study includes adult patients with low-risk thrombotic antiphospholipid syndrome managed in routine clinical practice at Internal Medicine units in Spain. Eligible patients have a history of venous thrombotic events and a low-risk antiphospholipid antibody profile and are treated with either direct oral anticoagulants or vitamin K antagonists at the discretion of the treating physician. The study combines retrospective and prospective data collection and does not involve any intervention beyond standard clinical care.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (≥18 years) with a diagnosis of thrombotic antiphospholipid syndrome.
  • Low-risk antiphospholipid syndrome defined by previous venous thrombosis and a single or double positive antiphospholipid antibody profile (lupus anticoagulant, anticardiolipin antibodies, and/or anti-beta-2-glycoprotein I antibodies).
  • Patients receiving long-term anticoagulant treatment with direct oral anticoagulants or vitamin K antagonists according to routine clinical practice.
  • At least 2 weeks of continuous anticoagulant treatment before study inclusion.

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years.
  • Triple antiphospholipid antibody positivity.
  • History of arterial thrombosis.
  • Anticoagulation for indications other than secondary prevention of venous thrombosis related to antiphospholipid syndrome.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
600 participants (estimated)
Target follow-up
36 Months
Patient registry
Yes

Groups and cohorts

  • Patients with low-risk thrombotic antiphospholipid syndrome receiving direct oral anticoagulants

    Patients with low-risk thrombotic antiphospholipid syndrome receiving direct oral anticoagulants for secondary prevention of venous thrombosis according to routine clinical practice. Treatment choice is made by the treating physician, with no intervention

  • Patients with low-risk thrombotic antiphospholipid syndrome receiving vitamin K antagonist

    Patients with low-risk thrombotic antiphospholipid syndrome receiving vitamin K antagonists for secondary prevention of venous thrombosis according to routine clinical practice. Treatment choice is made by the treating physician, with no intervention

06

What researchers measure

Primary outcomes

  1. Occurrence of recurrent venous thrombosis

    Occurrence of recurrent venous thrombosis during follow-up.

    Time frame: 24 months

Other outcomes

  1. Major or clinically relevant non-major bleeding

    Occurrence of major bleeding or clinically relevant non-major bleeding events during follow-up.

    Time frame: 24 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Perales Fraile I, Martin Asenjo M, de Ancos Aracil CL, Torres Macho J, Saez Comet L, Martin Cascon M, Alijotas Reig J, Gonzalez Garcia A, Franco Moreno A. Real-world observational study to evaluate the effectiveness and safety of direct oral anticoagulants compared with vitamin K antagonists for secondary venous thrombosis prevention in low-risk thrombotic antiphospholipid syndrome patients: DOACS-APS protocol. Rev Clin Esp (Barc). 2026 Jun-Jul;226(6):502564. doi: 10.1016/j.rceng.2026.502564. Epub 2026 Apr 29. PubMed 42067060 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data that underlie the results reported in publications arising from this study will be made available upon reasonable request. Data will be shared after publication of the primary results, subject to approval by the study investigators and in accordance with applicable ethical and legal requirements. Requests must include a methodologically sound research proposal, and data will be provided under a data sharing agreement to ensure participant confidentiality.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Dec 2028, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2026
First posted
Jan 28, 2026
StartActual
Dec 1, 2025
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07372170
Lead sponsor
Infanta Leonor University Hospital
Collaborators
pInvestiga
Responsible party
Anabel Franco Moreno (Principal Investigator, Infanta Leonor University Hospital) — Principal investigator
First posted
Jan 28, 2026
Start date
Dec 1, 2025
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jan 30, 2026

Study contacts

Anabel Franco Moreno, MD, PhD
Contact
afranco278@hotmail.com
+34686102661
Isabel Perales Fraile, MD
Contact
isabelperalesf@gmail.com
Anabel Franco-Moreno, MD, PhD
principal investigator · Sociedad Española De Medicina Interna

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion